Senators Optimistic As Sunscreen Bill Heads For HELP Committee Markup
This article was originally published in The Tan Sheet
Executive Summary
Ahead of a Sept. 17 committee markup of the Senate’s Sunscreen Innovation Act, bill sponsors and stakeholders held a briefing on Capitol Hill to generate support for the legislation, which has already passed in the House. The bill, S. 2141, has 15 co-sponsors and is expected to advance through committee to the Senate floor.
You may also be interested in...
Merck’s Keytruda Opens Door, But Combination Trials Could Unlock Efficacy
FDA’s approval of Merck’s anti-PD-1 drug pembrolizumab in melanoma marks a major milestone for oncology and industry’s immune checkpoint efforts. But with an overall response rate in labeling of 24%, there’s still room for improvement with combinations and use in earlier lines of therapy.
L’Oreal Falls Short On Safety, Efficacy, Adverse Event Data
FDA says it needs additional data from L’Oreal on safety, efficacy and adverse events to determine GRASE for drometrizole trisiloxane.
All OTC Ingredient TEAs Get Review Deadlines In Senate Draft Bill
Senate HELP Committee leaders release a draft bill that expands on changes proposed in the House’s Sunscreen Innovation Act by requiring deadlines for FDA review of all OTC ingredient TEAs. In a draft bill, Chairman Tom Harkin and other HELP members propose setting “reasonable” deadlines for TEA reviews.